Work

Bone Marrow Stoma Secretes a Soluble Factor That Protects Leukemia Cells From Cytarabine Induced Apoptosis by Bloking ENT Activity

Year: 2011

Type: article

Abstract: Despite a high response rate to chemotherapy, the vast majority of patients with AML are destined to relapse due to residual disease in the bone marrow (BM). The tumor microenvironment is increasingly being recognized as a critical factor in mediating cancer development and drug resistance. Leukemia cell mobilization in vivo by the CXCR4 inhibitor, AMD3100 induced chemosensitization to AraC, which translated into a significant survival advantage in mice (Nervi et al., 2009).

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2010.12.280